Octarine Bio, a synthetic biology startup based in Copenhagen, has raised EUR 4.35 million (USD 4.6 million) in a funding round led by Unconventional Ventures, with participation from Óskare Capital, The Footprint Firm, and dsm-firmenich Venturing. This raises Octarine's overall funding to EUR 12 million (USD 12.8 million).
The new funds will be channeled toward fast-tracking the development and market launch of the company's sustainable dyes product line.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.